Dissecting the relative contribution of OATP1B1-mediated uptake of xenobiotics into human hepatocytes using siRNA

References

• Aleku M, Schulz P, Keil O, et al. (2008). Atu027, a liposomal small interfering RNA formulation targeting protein kinase N3, inhibits cancer progression. Cancer Res 68:9788–98
   PubMed Web of Science ®Google Scholar
• Asberg A, Hartmann A, Fjeldsa E, et al. (2001). Bilateral pharmacokinetic interaction between cyclosporine A and atorvastatin in renal transplant recipients. Am J Transplant 1:382–6
   PubMed Web of Science ®Google Scholar
• Brown HS, Ito K, Galetin A, Houston JB. (2005). Prediction of in vivo drug--drug interactions from in vitro data: impact of incorporating parallel pathways of drug elimination and inhibitor absorption rate constant. Br J Clin Pharmacol 60:508–18
   PubMed Web of Science ®Google Scholar
• Cui Y, Konig J, Leier I, et al. (2001). Hepatic uptake of bilirubin and its conjugates by the human organic anion transporter SLC21A6. J Biol Chem 276:9626–30
   PubMed Web of Science ®Google Scholar
• De Fougerolles A, Vornlocher HP, Maraganore J, Lieberman J. (2007). Interfering with disease: a progress report on siRNA-based therapeutics. Nat Rev Drug Discov 6:443–53
   PubMed Web of Science ®Google Scholar
• Degorter MK, Ho RH, Leake BF, et al. (2012). Interaction of three regiospecific amino acid residues is required for OATP1B1 gain of OATP1B3 substrate specificity. Mol Pharm 9:986–95
   PubMedGoogle Scholar
• Fire A, Xu S, Montgomery MK, et al. (1998). Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans. Nature 391:806–11
   PubMed Web of Science ®Google Scholar
• Hagenbuch B, Gui C. (2008). Xenobiotic transporters of the human organic anion transporting polypeptides (OATP) family. Xenobiotica 38:778–801
   PubMed Web of Science ®Google Scholar
• Hartkoorn RC, Kwan WS, Shallcross V, et al. (2010). HIV protease inhibitors are substrates for OATP1A2, OATP1B1 and OATP1B3 and lopinavir plasma concentrations are influenced by SLCO1B1 polymorphisms. Pharmacogenet Genomics 20:112–20
   PubMed Web of Science ®Google Scholar
• Hedman M, Neuvonen PJ, Neuvonen M, et al. (2004). Pharmacokinetics and pharmacodynamics of pravastatin in pediatric and adolescent cardiac transplant recipients on a regimen of triple immunosuppression. Clin Pharmacol Ther 75:101–9
   PubMed Web of Science ®Google Scholar
• Hirano M, Maeda K, Shitara Y, Sugiyama Y. (2004). Contribution of OATP2 (OATP1B1) and OATP8 (OATP1B3) to the hepatic uptake of pitavastatin in humans. J Pharmacol Exp Ther 311:139–46
   PubMed Web of Science ®Google Scholar
• Hirano M, Maeda K, Shitara Y, Sugiyama Y. (2006). Drug--drug interaction between pitavastatin and various drugs via OATP1B1. Drug Metab Dispos 34:1229–36
   PubMed Web of Science ®Google Scholar
• Ieiri I, Suwannakul S, Maeda K, et al. (2007). SLCO1B1 (OATP1B1, an uptake transporter) and ABCG2 (BCRP, an efflux transporter) variant alleles and pharmacokinetics of pitavastatin in healthy volunteers. Clin Pharmacol Ther 82:541–7
   PubMed Web of Science ®Google Scholar
• Jones HM, Barton HA, Lai Y, et al. (2012). Mechanistic pharmacokinetic modeling for the prediction of transporter-mediated disposition in humans from sandwich culture human hepatocyte data. Drug Metab Dispos 40:1007–17
   PubMed Web of Science ®Google Scholar
• Karlgren M, Vildhede A, Norinder U, et al. (2012). Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug--drug interactions. J Med Chem 55:4740–63
   PubMed Web of Science ®Google Scholar
• Kitamura S, Maeda K, Wang Y, Sugiyama Y. (2008). Involvement of multiple transporters in the hepatobiliary transport of rosuvastatin. Drug Metab Dispos 36:2014–23
   PubMed Web of Science ®Google Scholar
• Kotani N, Maeda K, Watanabe T, et al. (2011). Culture period-dependent changes in the uptake of transporter substrates in sandwich-cultured rat and human hepatocytes. Drug Metab Dispos 39:1503–10
   PubMed Web of Science ®Google Scholar
• Kullak-Ublick GA, Ismair MG, Stieger B, et al. (2001). Organic anion-transporting polypeptide B (OATP-B) and its functional comparison with three other OATPs of human liver. Gastroenterology 120:525–33
   PubMed Web of Science ®Google Scholar
• Liao M, Raczynski AR, Chen M, et al. (2010). Inhibition of hepatic organic anion-transporting polypeptide by RNA interference in sandwich-cultured human hepatocytes: an in vitro model to assess transporter-mediated drug--drug interactions. Drug Metab Dispos 38:1612–22
   PubMed Web of Science ®Google Scholar
• Maeda K, Ieiri I, Yasuda K, et al. (2006). Effects of organic anion transporting polypeptide 1B1 haplotype on pharmacokinetics of pravastatin, valsartan, and temocapril. Clin Pharmacol Ther 79:427–39
   PubMed Web of Science ®Google Scholar
• McGinnity DF, Collington J, Austin RP, Riley RJ. (2007). Evaluation of human pharmacokinetics, therapeutic dose and exposure predictions using marketed oral drugs. Curr Drug Metab 8:463–79
   PubMed Web of Science ®Google Scholar
• Miyagawa M, Maeda K, Aoyama A, Sugiyama Y. (2009). The eighth and ninth transmembrane domains in organic anion transporting polypeptide 1B1 affect the transport kinetics of estrone-3-sulfate and estradiol-17beta-D-glucuronide. J Pharmacol Exp Ther 329:551–7
   PubMed Web of Science ®Google Scholar
• Neuvonen PJ, Niemi M, Backman JT. (2006). Drug interactions with lipid-lowering drugs: mechanisms and clinical relevance. Clin Pharmacol Ther 80:565–81
   PubMed Web of Science ®Google Scholar
• Niemi M, Pasanen MK, Neuvonen PJ. (2011). Organic anion transporting polypeptide 1B1: a genetically polymorphic transporter of major importance for hepatic drug uptake. Pharmacol Rev 63:157–81
   PubMed Web of Science ®Google Scholar
• Noe J, Portmann R, Brun ME, Funk C. (2007). Substrate-dependent drug-drug interactions between gemfibrozil, fluvastatin and other organic anion-transporting peptide (OATP) substrates on OATP1B1, OATP2B1, and OATP1B3. Drug Metab Dispos 35:1308–14
   PubMed Web of Science ®Google Scholar
• Olbricht C, Wanner C, Eisenhauer T, et al. (1997). Accumulation of lovastatin, but not pravastatin, in the blood of cyclosporine-treated kidney graft patients after multiple doses. Clin Pharmacol Ther 62:311–21
   PubMed Web of Science ®Google Scholar
• Paine SW, Parker AJ, Gardiner P, et al. (2008). Prediction of the pharmacokinetics of atorvastatin, cerivastatin, and indomethacin using kinetic models applied to isolated rat hepatocytes. Drug Metab Dispos 36:1365–74
   PubMed Web of Science ®Google Scholar
• Pasanen MK, Fredrikson H, Neuvonen PJ, Niemi M. (2007). Different effects of SLCO1B1 polymorphism on the pharmacokinetics of atorvastatin and rosuvastatin. Clin Pharmacol Ther 82:726–33
   PubMed Web of Science ®Google Scholar
• Poirier A, Cascais AC, Funk C, Lave T. (2009). Prediction of pharmacokinetic profile of valsartan in human based on in vitro uptake transport data. J Pharmacokinet Pharmacodyn 36:585–611
   PubMed Web of Science ®Google Scholar
• Poirier A, Lave T, Portmann R, et al. (2008). Design, data analysis, and simulation of in vitro drug transport kinetic experiments using a mechanistic in vitro model. Drug Metab Dispos 36:2434–44
   PubMed Web of Science ®Google Scholar
• Regazzi MB, Iacona I, Campana C, et al. (1993). Altered disposition of pravastatin following concomitant drug therapy with cyclosporin A in transplant recipients. Transplant Proc 25:2732–4
   PubMed Web of Science ®Google Scholar
• Riley RJ. (2001). The potential pharmacological and toxicological impact of P450 screening. Curr Opin Drug Discov Devel 4:45–54
   PubMedGoogle Scholar
• Santel A, Aleku M, Keil O, et al. (2006a). A novel siRNA-lipoplex technology for RNA interference in the mouse vascular endothelium. Gene Ther 16:1222–34
   Google Scholar
• Santel A, Aleku M, Keil O, et al. (2006b). RNA interference in the mouse vascular endothelium by systemic administration of siRNA-lipoplexes for cancer therapy. Gene Ther 18:1360–70
   Google Scholar
• Shitara Y, Horie T, Sugiyama Y. (2006). Transporters as a determinant of drug clearance and tissue distribution. Eur J Pharm Sci 27:425–46
   PubMed Web of Science ®Google Scholar
• Simonson SG, Raza A, Martin PD, et al. (2004). Rosuvastatin pharmacokinetics in heart transplant recipients administered an antirejection regimen including cyclosporine. Clin Pharmacol Ther 76:167–77
   PubMed Web of Science ®Google Scholar
• Soars, MG, Barton P, Ismair M, et al. (2012). The development, characterization, and application of an OATP1B1 inhibition assay in drug discovery. Drug Metab Dispos 40:1641–8
   PubMed Web of Science ®Google Scholar
• Soars MG, Grime K, Sproston JL, et al. (2007a). Use of hepatocytes to assess the contribution of hepatic uptake to clearance in vivo. Drug Metab Dispos 35:859–65
   PubMed Web of Science ®Google Scholar
• Soars MG, McGinnity DF, Grime K, Riley RJ. (2007b). The pivotal role of hepatocytes in drug discovery. Chem Biol Interact 168:2–15
   PubMed Web of Science ®Google Scholar
• Soars MG, Webborn PJ, Riley RJ. (2009). Impact of hepatic uptake transporters on pharmacokinetics and drug--drug interactions: use of assays and models for decision making in the pharmaceutical industry. Mol Pharm 6:1662–77
   PubMed Web of Science ®Google Scholar
• Suwannakul S, Ieiri I, Kimura M, et al. (2008). Pharmacokinetic interaction between pravastatin and olmesartan in relation to SLCO1B1 polymorphism. J Hum Genet 53:899–904
   PubMed Web of Science ®Google Scholar
• Vaishnaw AK, Gollob J, Gamba-Vitalo C, et al. (2010). A status report on RNAi therapeutics. Silence 1:1--13 , Article no. 14
   PubMedGoogle Scholar
• Venkatakrishnan K, Von Moltke LL, Greenblatt DJ. (1998). Relative quantities of catalytically active CYP 2C9 and 2C19 in human liver microsomes: application of the relative activity factor approach. J Pharm Sci 87:845–53
   PubMed Web of Science ®Google Scholar
• Watanabe T, Kusuhara H, Debori Y, et al. (2011). Prediction of the overall renal tubular secretion and hepatic clearance of anionic drugs and a renal drug--drug interaction involving organic anion transporter 3 in humans by in vitro uptake experiments. Drug Metab Dispos 39:1031–8
   PubMed Web of Science ®Google Scholar
• Watanabe, T, Kusuhara H, Maeda K, et al. (2010). Investigation of the rate-determining process in the hepatic elimination of HMG-CoA reductase inhibitors in rats and humans. Drug Metab Dispos 38:215–22
   PubMed Web of Science ®Google Scholar
• Yabe Y, Galetin A, Houston JB. (2011). Kinetic characterization of rat hepatic uptake of 16 actively transported drugs. Drug Metab Dispos 39:1808–14
   PubMed Web of Science ®Google Scholar
• Yamada A, Maeda K, Kamiyama E, et al. (2007). Multiple human isoforms of drug transporters contribute to the hepatic and renal transport of olmesartan, a selective antagonist of the angiotensin II AT1-receptor. Drug Metab Dispos 35:2166–76
   PubMed Web of Science ®Google Scholar
• Yamashiro W, Maeda K, Hirouchi M, et al. (2006). Involvement of transporters in the hepatic uptake and biliary excretion of valsartan, a selective antagonist of the angiotensin II AT1-receptor, in humans. Drug Metab Dispos 34:1247–54
   PubMed Web of Science ®Google Scholar
• Yu AM. (2007). Small interfering RNA in drug metabolism and transport. Curr Drug Metab 8:700–8
   PubMed Web of Science ®Google Scholar
• Yue W, Abe K, Brouwer KL. (2009). Knocking down breast cancer resistance protein (Bcrp) by adenoviral vector-mediated RNA interference (RNAi) in sandwich-cultured rat hepatocytes: a novel tool to assess the contribution of Bcrp to drug biliary excretion. Mol Pharm 6:134–43
   PubMed Web of Science ®Google Scholar